| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697315 | Bulletin du Cancer | 2017 | 9 Pages |
Abstract
Immune checkpoint blockade by the use of anti-PD(L)1 or anti-CTLA4 antibodies can induce long lasting disease response and maybe cure in a lot of advanced cancer patients. This ongoing immunotherapy revolution has given new hope to cancer patients and oncologists. However, still the majority of cancer patients do not respond to immune checkpoint blockade and novel therapeutical possibilities are being tested in several clinical trials. One of the possibilities to enhance responses to immune checkpoint blockade is the combination with chemotherapy or with other immune checkpoint blockade molecules. In this review, we explore the preclinical rational for this synergism and the potential consequences for immunotherapy in oncology.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Gaëlle Douchet, Sandrine Aspeslagh,